{"entity":{"id":"nct06483100","kind":"trial","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","aka":[],"tldr":"A phase 2 trial of clonoSEQ in Multiple myeloma, run by Washington University School of Medicine, now recruiting.","summary":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance is a phase 2 interventional study registered as NCT06483100 by Washington University School of Medicine, with 65 participants planned, started 2024-12-20 and due to reach its primary completion in 2032-06-30. Interventions recorded: Elrantamab, clonoSEQ. Conditions recorded: Multiple Myeloma.\n\nLinked to the drug clonoSEQ because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06483100","url":"https://clinicaltrials.gov/study/NCT06483100"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["clonoseq"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06483100","phase":"2","setting":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","sponsor":"Washington University School of Medicine","enrolled":65,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06483100/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/"}]}}